IDEMIA
5.10.2020 11:05:07 CEST | Business Wire | Press release
In the context of a rapid transformation of the banking industry, IDEMIA, the global leader in Augmented Identity, supports FinTechs and neobanks with the launch of the Global Fintech Accelerator Card Program. This new program allows a rapid process from cardholder onboarding - to card issuance.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20201005005366/en/
IDEMIA’s leadership in card manufacturing, as the number 1 global FinTech card issuance partner, is based on a solid experience of a global dedicated FinTech team and a network of 30 Service Centers in 26 countries around the world. FinTechs can leverage the capability and know-how of IDEMIA to enable card issuance into the marketplace anywhere in the world.
Over the years, IDEMIA has built the largest world wide network of personalization centers designed to optimize responsiveness and proximity to the cardholder for fast delivery times. All of the 30 Service Centers are supported by a Common Personalization System (CPS) that allows card profile developments to be instantly and securely transferred and re-used in any one of them, helping globally aspiring Fintechs to expand rapidly. In addition to CPS, all IDEMIA sites are inter-connected via the IDEMIA Hub with a connection to almost all local and global card processors and BaaS providers so that services and solutions can be safely replicated, extended, shared and optimized across the world.
The IDEMIA FinTech Accelerator CardProgram benefits from dedicated local, regional and global FinTech teams that are trained to help to create a card product that will ensure FInTechs can fully differentiate their product in the marketplace. Before manufacturing the cards, the needs of various stakeholders within the FinTech’s organization are taken into consideration to guarantee an optimal start of the card issuing journey. IDEMIA provides advice on how to use innovative solutions to help FinTechs to further differentiate such as card packaging solutions, IDEMIA metal cards, biometric cards (F.CODE), cards with a dynamic security code (MOTION CODE) and recycled cards (GREENPAY).
With IDEMIA’s digital assets, customers will be able to blend the physical card with digital services. The FinTech Accelerator Card Program not only provides a seamless process for a successful card launch, but also it delivers additional digital services such as mobile identity proofing for customer on-boarding and IDEMIA Card Connect, a way to activate a card or provide secure customer authentication by tapping the contactless card on the phone. IDEMIA’s digital assets can also enable FinTechs to enrich their mobile banking apps with new payment features via digital cards, reinventing the customer journey for both proximity and remote payments.
“We recognize that the FinTech world needs innovative solutions and to move quickly. Our Accelerator Card Program does just that and ensures that we can help the processors, BaaS providers and FinTech customers get their products to market as quickly as possible and expand globally without the need to start a new project in each country”
Stuart Yaxley | Senior Vice President Global Accounts and FinTechs for Financial Institutions at IDEMIA
“IDEMIA’s FinTech accelerator card program and Hub have been strategic levers in creating an advanced interface and facilitating business for all of our existing and future global fintech customers, including providing a wide variety of valuable solutions such as metal cards, recycled plastic cards and digital solutions. The IDEMIA FinTech team are extremely knowledgeable in their field, and with our combined global reach, our partnership is a powerful force as we support our customer’s international growth journeys. Moreover, their global service delivery team have made sure that the interface that we have set up with them is designed to work with all of the needs and expectations of our customers.”
Neil Harris | Group Chief Commercial Officer of GPS - Global Processing Services.
“We at OneCard have set out to reimagine Credit Cards and have launched a Mobile First Metal Credit Card. We needed a partner who has the same philosophy and outlook of innovation and consumer first. The IDEMIA FinTech team was our partner of choice to create the stunning 16 g Metal OneCard. Their personalized Metal Card offering has helped differentiate OneCard. IDEMIA has been able to deliver the product for us in these challenging times also. ”
Vibhav Hathi, Cofounder & CMO, OneCard
About IDEMIA
IDEMIA, the global leader in Augmented Identity, provides a trusted environment enabling citizens and consumers alike to perform their daily critical activities (such as pay, connect and travel), in the physical as well as digital space.
Securing our identity has become mission critical in the world we live in today. By standing for Augmented Identity, an identity that ensures privacy and trust and guarantees secure, authenticated and verifiable transactions, we reinvent the way we think, produce, use and protect one of our greatest assets – our identity – whether for individuals or for objects, whenever and wherever security matters. We provide Augmented Identity for international clients from Financial, Telecom, Identity, Public Security and IoT sectors.
With close to 15,000 employees around the world, IDEMIA serves clients in 180 countries.
For more information, visit www.idemia.com / Follow @IDEMIAGroup on Twitter
View source version on businesswire.com: https://www.businesswire.com/news/home/20201005005366/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
U.S. FDA Approves Takeda’s ORZEYFUL™ (oveporexton), the First and Only Medicine to Treat the Underlying Cause of Narcolepsy Type 16.8.2026 00:10:00 CEST | Press release
Adults Taking ORZEYFUL Experienced Significant and Meaningful Improvements Across the Full Range of Symptoms of Narcolepsy Type 1 (NT1) in Clinical Trials Compared to Those on Placebo As a First-in-Class Orexin Treatment, ORZEYFUL has the Potential to Redefine NT1 Care Beyond Individual Symptoms Takeda is Advancing U.S. Launch Preparations and Expects to Make ORZEYFUL Available Following Completion of the Drug Enforcement Administration (DEA) Scheduling Process Takeda (TSE:4502/NYSE:TAK) announced that the U.S. Food and Drug Administration (FDA) approved ORZEYFUL™ (oveporexton), an oral orexin receptor 2 (OX2R) agonist, for the treatment of narcolepsy type 1 (NT1, narcolepsy with cataplexy) in adults.* The persistent 24-hour nature of NT1 is driven by orexin deficiency and can severely impact people’s lives. As a first-in-class orexin treatment, ORZEYFUL is the only medicine indicated in the U.S. to treat the disease holistically rather than individual symptoms. “The FDA approval of OR
Compass Pathways Announces New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)5.8.2026 22:30:00 CEST | Press release
Compass Pathways plc (Nasdaq: CMPS), a biotechnology company dedicated to unlocking urgently needed new treatment options in mental health care, announced today that Compass granted equity awards under the Compass Pathways plc 2026 Inducement Plan to fourteen newly hired non-executive employees. The equity awards were granted on August 3, 2026 and consisted of options to purchase an aggregate of 139,355 shares and restricted share units or, in the case of employees in the United Kingdom nominal cost options, covering an aggregate of 66,300 shares. The options have an exercise price per share equal to $11.25, the closing price of the Company’s American Depositary Shares on the Nasdaq Global Select Market on the grant date, and will vest over a four-year period with 25% vesting on the first anniversary of the date of the grant and the remaining 75% vesting in equal monthly installments over the three-year period thereafter, subject to each employee’s continued employment. The restricted
Clinilabs Announces Medical Leadership Appointments5.8.2026 16:05:00 CEST | Press release
Bob Dagher, M.D., Named Chief Medical Officer and Waqar Ahmed Siddiqui, M.D., Named Principal Investigator Clinilabs (“Clinilabs LLC”), a global, full-service contract research organization (CRO) specializing in central nervous system (CNS) drug and device development, today announced the appointments of Bob Dagher, M.D., as Chief Medical Officer and Waqar Ahmed Siddiqui, M.D., as Principal Investigator of the Company’s Eatontown, New Jersey Clinical Research Unit (CRU). Dr. Dagher will provide strategic and medical leadership across the organization, while Dr. Siddiqui will lead the execution of research projects at the Company’s CRU. Together, they will support the design, development, and execution of clinical programs for pharmaceutical, biotechnology, and medical device sponsors advancing innovative therapies for psychiatric, neurological, substance use, and rare CNS disorders. “Clinilabs has earned the trust of sponsors by combining deep scientific expertise, medical leadership,
Interactive Brokers Adds Brazilian Futures through Brazil’s B3 Exchange5.8.2026 16:00:00 CEST | Press release
Interactive Brokers (Nasdaq: IBKR), an automated global broker, today announced that eligible clients outside of Brazil can now trade Brazilian futures in addition to equities through the B3 exchange. Interactive Brokers was the first broker to provide international investors with streamlined, low-cost access to B3. Offering Brazilian futures and equities alongside products across more than 170 markets worldwide underscores IBKR’s commitment to broadening global market access and giving clients efficient, cost-effective ways to diversify through a single, unified platform. Access to B3 provides exposure to one of Latin America’s most active and liquid markets, providing long-term growth potential across multiple sectors and another way for investors to pursue emerging market opportunities. "Global investors deserve seamless, low-cost access to the world's most compelling markets, including emerging economies shaping tomorrow's financial landscape," said Milan Galik, Chief Executive Off
Speech Processing Solutions Launches Philips SpeechLive Legal AI Assistant for Faster, More Accurate Legal Document Creation5.8.2026 15:37:00 CEST | Press release
The new SpeechLive Legal AI Assistant reduces the administrative burden on legal professionals through customizable document drafting powered by speech recognition tuned for legal terminology Speech Processing Solutions, the global leader in AI-assisted professional dictation and documentation solutions sold under the Philips brand, today announced the Philips SpeechLive Legal AI Assistant. The new solution transforms voice recordings, dictation and uploaded sources into structured, ready-to-review legal documents, helping legal professionals work faster while retaining control of the final draft. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260805997413/en/ The new Philips SpeechLive Legal AI Assistant is designed for turning conversations into ready-to-review legal document drafts. SpeechLive Legal significantly reduces the time needed to transform voice input into structured legal documentation, delivering consistent an
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
